2009
Incidence, Prevalence, and Clinical Significance of Abnormal Hematologic Indices in Compensated Cirrhosis
Qamar AA, Grace ND, Groszmann RJ, Garcia–Tsao G, Bosch J, Burroughs AK, Ripoll C, Maurer R, Planas R, Escorsell A, Garcia–Pagan J, Patch D, Matloff DS, Makuch R, Rendon G, Group P. Incidence, Prevalence, and Clinical Significance of Abnormal Hematologic Indices in Compensated Cirrhosis. Clinical Gastroenterology And Hepatology 2009, 7: 689-695. PMID: 19281860, PMCID: PMC4545534, DOI: 10.1016/j.cgh.2009.02.021.Peer-Reviewed Original ResearchConceptsHepatic venous pressure gradientHematologic indicesCompensated cirrhosisBaseline hepatic venous pressure gradientWhite blood cell countChild-Pugh scorePredictors of deathPrimary end pointVenous pressure gradientDevelopment of varicesKaplan-Meier analysisBlood cell countCombination of leukopeniaBaseline thrombocytopeniaVariceal bleedingClinical decompensationEsophageal varicesPrognostic significanceTransplant surgeryClinical significanceLeukopeniaThrombocytopeniaCirrhosisCell countVarices
2000
The Stroke Prognosis Instrument II (SPI-II)
Kernan W, Viscoli C, Brass L, Makuch R, Sarrel P, Roberts R, Gent M, Rothwell P, Sacco R, Liu R, Boden-Albala B, Horwitz R. The Stroke Prognosis Instrument II (SPI-II). Stroke 2000, 31: 456-462. PMID: 10657422, DOI: 10.1161/01.str.31.2.456.Peer-Reviewed Original ResearchMeSH KeywordsAgedFemaleHumansIschemic Attack, TransientMaleMiddle AgedPredictive Value of TestsPrognosisStrokeConceptsRisk groups ICongestive heart failurePooled rateRisk groupsGroup IPrior strokeSPI-IIHeart failureOutcome ratesTest cohortPooled outcome ratesTransient ischemic attackCoronary artery diseasePatient risk groupsStroke Prognosis Instrument IIReceiver operator characteristic analysisOperator characteristic analysisIschemic attackIschemic strokeArtery diseaseIndex eventPatient counselingNew predictive variablesStrokeTotal score
1999
The Etiology and Outcome of Cerebral Ventriculomegaly at Term in Very Low Birth Weight Preterm Infants
Ment L, Vohr B, Allan W, Westerveld M, Katz K, Schneider K, Makuch R. The Etiology and Outcome of Cerebral Ventriculomegaly at Term in Very Low Birth Weight Preterm Infants. Pediatrics 1999, 104: 243-248. PMID: 10429002, DOI: 10.1542/peds.104.2.243.Peer-Reviewed Original ResearchConceptsBronchopulmonary dysplasiaPreterm infantsCorrected ageIndependent predictorsCerebral ventriculomegalyBirth weightGrade 3Low birth weight preterm infantsBirth weight preterm infantsMaternal educationLow birth weight survivorsCause of ventriculomegalyDevelopment of ventriculomegalyGrades of IVHIncidence of handicapWeight preterm infantsMonths' corrected ageAdverse neurodevelopmental outcomesLow birth weightYears' corrected ageAdverse cognitive outcomesLogistic regression analysisYears of ageApgar scoreNeurodevelopmental handicapStratified Randomization for Clinical Trials
Kernan W, Viscoli C, Makuch R, Brass L, Horwitz R. Stratified Randomization for Clinical Trials. Journal Of Clinical Epidemiology 1999, 52: 19-26. PMID: 9973070, DOI: 10.1016/s0895-4356(98)00138-3.Peer-Reviewed Original ResearchConceptsStratified randomizationSmall trialsInterim analysisActive-control equivalence trialsClinical factorsLarge trialsSuperiority trialSubgroup analysisClinical trialsTreatment responsivenessTreatment outcomesMEDLINE searchTreatment groupsStratification factorsEquivalence trialPrognosisTrialsRandomizationType ITheoretical benefitsImportance of stratificationStratificationSample sizeInvestigatorsPatients
1989
Survival in Children with Perinatally Acquired Human Immunodeficiency Virus Type 1 Infection
Scott G, Hutto C, Makuch R, Mastrucci M, O'Connor T, Mitchell C, Trapido E, Parks W. Survival in Children with Perinatally Acquired Human Immunodeficiency Virus Type 1 Infection. New England Journal Of Medicine 1989, 321: 1791-1796. PMID: 2594038, DOI: 10.1056/nejm198912283212604.Peer-Reviewed Original ResearchConceptsMedian survivalMedian ageHuman immunodeficiency virus type 1 (HIV-1) infectionHuman immunodeficiency virus type 1Virus type 1 infectionImmunodeficiency virus type 1Common first manifestationLymphoid interstitial pneumoniaIntravenous drug useProportional hazards analysisTime of diagnosisPneumocystis carinii pneumoniaHIV-1 infectionMedian survival timeType 1 infectionRecurrent bacterial infectionsJackson Memorial HospitalLong-term survivalYears of ageVirus type 1Candida esophagitisProgressive diseaseAntiviral treatmentBlood transfusionInterstitial pneumoniaGoodman and Kruskal's λ: A new look at an old measure of association
Makuch R, Rosenberg P, Scott G. Goodman and Kruskal's λ: A new look at an old measure of association. Statistics In Medicine 1989, 8: 619-631. PMID: 2727480, DOI: 10.1002/sim.4780080511.Peer-Reviewed Original Research
1988
Identifying prognostic factors in binary outcome data: An application using liver function tests and age to predict liver metastases
Makuch R, Rosenberg P, Mulshine J. Identifying prognostic factors in binary outcome data: An application using liver function tests and age to predict liver metastases. Statistics In Medicine 1988, 7: 843-856. PMID: 2842852, DOI: 10.1002/sim.4780070803.Peer-Reviewed Original ResearchConceptsLiver function testsLiver metastasesFunction testsOutcome dataSmall cell lung cancerImportant prognostic variablesCell lung cancerLogistic regression modelsPrognostic factorsLung cancerPrognostic variablesMetastasisBinary outcome dataSpecific guidelinesRegression modelsAgeStandard logistic regression model
1987
myc family oncogene amplification in tumor cell lines established from small cell lung cancer patients and its relationship to clinical status and course.
Johnson B, Ihde D, Makuch R, Gazdar A, Carney D, Oie H, Russell E, Nau M, Minna J. myc family oncogene amplification in tumor cell lines established from small cell lung cancer patients and its relationship to clinical status and course. Journal Of Clinical Investigation 1987, 79: 1629-1634. PMID: 3034978, PMCID: PMC424486, DOI: 10.1172/jci112999.Peer-Reviewed Original ResearchConceptsMyc family DNA amplificationPatient tumorsTumor cell linesC-myc amplificationCell linesSmall cell lung cancer patientsCell lung cancer patientsSmall cell lung cancer cell linesCell lung cancer cell linesExtensive-stage patientsLung cancer patientsLung cancer cell linesCancer cell linesRelapsed patientsStage patientsClinical statusCancer patientsChemotherapy treatmentPatientsTumorsDNA amplificationOncogene amplificationEvaluation of circulating malignant cells provides prognostic information in cutaneous T cell lymphoma.
Schechter G, Sausville E, Fischmann A, Soehnlen F, Eddy J, Matthews M, Gazdar A, Guccion J, Munson D, Makuch R. Evaluation of circulating malignant cells provides prognostic information in cutaneous T cell lymphoma. Blood 1987, 69: 841-9. PMID: 3493044, DOI: 10.1182/blood.v69.3.841.bloodjournal693841.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaT-cell lymphomaBlood involvementLymphocyte morphologyRisk factorsCell lymphomaCTCL cellsIndependent risk factorExtent of diseasePretreatment risk factorsPeripheral blood lymphocyte morphologyUntreated patientsVisceral diseaseWorse survivalLymph nodesInitial diagnosisT stageAggressive featuresSkin stageCutaneous tumorsSkin plaquesPrognostic informationPatientsMalignant cellsMultivariate analysisCytologic transformation in cutaneous T cell lymphoma: a clinicopathologic entity associated with poor prognosis.
Dmitrovsky E, Matthews M, Bunn P, Schechter G, Makuch R, Winkler C, Eddy J, Sausville E, Ihde D. Cytologic transformation in cutaneous T cell lymphoma: a clinicopathologic entity associated with poor prognosis. Journal Of Clinical Oncology 1987, 5: 208-15. PMID: 3492594, DOI: 10.1200/jco.1987.5.2.208.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaT-cell lymphomaCytologic transformationCell lymphomaClinical courseClinicopathologic entityCutaneous T-cell lymphoma patientsTumor cell DNA contentT-cell lymphoma patientsAggressive clinical courseDistinct clinicopathologic entityCell lymphoma patientsPeripheral blood smearMalignant T cellsLarge cell lymphomaConvoluted lymphocytesMedian survivalVisceral sitesLymph nodesOccasional patientMedian timeLymphoma patientsPoor prognosisCell DNA contentT cells
1986
Late intensive combined modality therapy followed by autologous bone marrow infusion in extensive-stage small-cell lung cancer.
Ihde D, Deisseroth A, Lichter A, Bunn P, Carney D, Cohen M, Veach S, Makuch R, Johnston-Early A, Abrams R. Late intensive combined modality therapy followed by autologous bone marrow infusion in extensive-stage small-cell lung cancer. Journal Of Clinical Oncology 1986, 4: 1443-54. PMID: 3020181, DOI: 10.1200/jco.1986.4.10.1443.Peer-Reviewed Original ResearchConceptsExtensive-stage SCLC patientsProphylactic cranial irradiationComplete responseAutologous bone marrowPartial responseSCLC patientsModality therapyTumor regressionMedical conditionsExtensive-stage small-cell lung cancer patientsExtensive-stage small-cell lung cancerSmall cell lung cancer patientsAutologous bone marrow infusionMajor non-hematologic toxicitySmall cell lung cancerExtensive-stage patientsNon-hematologic toxicitiesWeeks of cyclophosphamideWeeks of vincristineBone marrow infusionGood medical conditionPoor medical conditionLung cancer patientsBetter tumor regressionCranial irradiationPulmonary toxicity with combined modality therapy for limited stage small-cell lung cancer.
Brooks B, Seifter E, Walsh T, Lichter A, Bunn P, Zabell A, Johnston-Early A, Edison M, Makuch R, Cohen M. Pulmonary toxicity with combined modality therapy for limited stage small-cell lung cancer. Journal Of Clinical Oncology 1986, 4: 200-9. PMID: 3003259, DOI: 10.1200/jco.1986.4.2.200.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Small CellCombined Modality TherapyCyclophosphamideDoxorubicinFemaleHumansLomustineLung NeoplasmsMaleMethotrexateMiddle AgedProcarbazinePrognosisProspective StudiesPulmonary FibrosisRadiographyRandom AllocationRespiratory Function TestsVincristineConceptsPulmonary function testsLimited stage small cell lung cancerStage small cell lung cancerSmall cell lung cancerModality therapyPulmonary toxicityPulmonary complicationsVital capacityLung cancerRadiation therapyLife-threatening pulmonary toxicityInitial pulmonary function testLower vital capacitySubsequent pulmonary complicationsBilateral pulmonary infiltratesDisease-free survivalModality armPulmonary infiltratesPulmonary morbidityExpiratory volumeOverall survivalPerformance statusProspective trialClinical courseHospital admission
1985
Histologic assessment of lymph nodes in mycosis fungoides/sézary syndrome (cutaneous T-cell lymphoma): Clinical correlations and prognostic import of a new classification system
Sausville E, Worsham G, Matthews M, Makuch R, Fischmann A, Schechter G, Gazdar A, Bunn P. Histologic assessment of lymph nodes in mycosis fungoides/sézary syndrome (cutaneous T-cell lymphoma): Clinical correlations and prognostic import of a new classification system. Human Pathology 1985, 16: 1098-1109. PMID: 3876976, DOI: 10.1016/s0046-8177(85)80177-5.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaLymph node biopsy specimensFive-year survivalLymph node architectureLymph nodesAtypical cellsHistopathologic featuresBiopsy specimensMycosis fungoides/Sézary syndromeLymph node biopsyAtypical lymphoid cellsT-cell lymphomaExtent of skinT-cell regionsLN subgroupAtypical lymphocytesNode biopsySézary syndromeVisceral involvementMycosis fungoidesInitial diagnosisParacortical zonePrognostic valueLN classHistopathologic classificationPrognostic factors in patients with hepatocellular carcinoma receiving systemic chemotherapy. Identification of two groups of patients with prospects for prolonged survival
Ihde D, Matthews M, Makuch R, McIntire K, Eddy J, Seeff L. Prognostic factors in patients with hepatocellular carcinoma receiving systemic chemotherapy. Identification of two groups of patients with prospects for prolonged survival. The American Journal Of Medicine 1985, 78: 399-406. PMID: 2579551, DOI: 10.1016/0002-9343(85)90330-4.Peer-Reviewed Original ResearchConceptsAlpha-fetoprotein levelsFibrolamellar carcinomaHepatocellular carcinomaSystemic chemotherapyNormal serum alpha-fetoprotein levelsHepatitis B serum markersNormal alpha-fetoprotein levelsSerum alpha-fetoprotein levelsElevated alpha-fetoprotein levelsAmbulatory performance statusHomogeneous clinical featuresAbsence of cirrhosisHepatitis B markersTime of diagnosisGroup of patientsInitiation of treatmentLack of jaundiceAmbulatory statusExtrahepatic metastasesPerformance statusImproved survivalIndolent coursePrognostic factorsClinical featuresSerum markers
1984
Predictive factors for tumor response to preoperative chemotherapy in patients with head and neck squamous carcinoma: The head and neck contracts program
Wolf G, Makuch R, Baker S. Predictive factors for tumor response to preoperative chemotherapy in patients with head and neck squamous carcinoma: The head and neck contracts program. Cancer 1984, 54: 2869-2877. PMID: 6208993, DOI: 10.1002/1097-0142(19841215)54:12<2869::aid-cncr2820541210>3.0.co;2-n.Peer-Reviewed Original ResearchConceptsSquamous cell carcinomaTumor responsePartial responsePreoperative chemotherapyComplete responseResponse rateTumor characteristicsCell carcinomaHigh tumor response ratesNeck squamous cell carcinomaNodal response ratesResectable stage IIIPatient performance statusPrimary tumor responseTumor response rateNational Cancer Institute trialsNeck squamous carcinomaVariety of patientsLarynx/Preoperative cisplatinChemotherapy regimenIntensive chemotherapyUntreated patientsAdvanced headPerformance statusA non‐parametric graphical representation of the relationship between survival and the occurrence of an event: Application to responder versus non‐responder bias
Simon R, Makuch R. A non‐parametric graphical representation of the relationship between survival and the occurrence of an event: Application to responder versus non‐responder bias. Statistics In Medicine 1984, 3: 35-44. PMID: 6729287, DOI: 10.1002/sim.4780030106.Peer-Reviewed Original Research
1983
Treatment of extensive stage small cell bronchogenic carcinoma Effects of variation in intensity of induction chemotherapy
Brower M, Ihde D, Johnston-Early A, Bunn P, Cohen M, Carney D, Makuch R, Matthews M, Radice P, Minna J. Treatment of extensive stage small cell bronchogenic carcinoma Effects of variation in intensity of induction chemotherapy. The American Journal Of Medicine 1983, 75: 993-1000. PMID: 6316784, DOI: 10.1016/0002-9343(83)90880-x.Peer-Reviewed Original ResearchConceptsHigh-intensity groupSmall cell bronchogenic carcinomaHigh-intensity therapyCell bronchogenic carcinomaInduction chemotherapyInduction courseInduction deathBronchogenic carcinomaDay 1Reversible congestive heart failureModerate-intensity therapyOverall median survivalCongestive heart failureSevere peripheral neuropathyModerate-intensity groupEvaluable patientsComplete remissionInduction therapyInfectious complicationsPartial remissionMedian survivalUntreated patientsComplete responseHeart failurePeripheral neuropathyDelayed hypersensitivity skin testing as a prognostic indicator in patients with small cell lung cancer
Johnston‐Early A, Cohen M, Fossieck B, Harwood S, Ihde D, Bunn P, Matthews M, Minna J, Makuch R. Delayed hypersensitivity skin testing as a prognostic indicator in patients with small cell lung cancer. Cancer 1983, 52: 1395-1400. PMID: 6311393, DOI: 10.1002/1097-0142(19831015)52:8<1395::aid-cncr2820520810>3.0.co;2-t.Peer-Reviewed Original ResearchConceptsSkin test reactivityGood performance statusLow tumor burdenTest reactivityAnergic patientsPerformance statusTumor burdenReactive patientsSmall cell lung cancer patientsHypersensitivity skin test reactivityCell lung cancer patientsSmall cell lung cancerGood prognosis patientsHypersensitivity skin testingCell lung cancerLung cancer patientsSkin test antigensPrognosis patientsSkin testingPoor prognosisPrognostic importancePrognostic utilityPrognostic indicatorCancer patientsLung cancer
1982
The clinical behavior of „mixed”︁ small cell/large cell bronchogenic carcinoma compared to „pure”︁ small cell subtypes
Radice P, Matthews M, Ihde D, Gazdar A, Carney D, Bunn P, Cohen M, Fossieck B, Makuch R, Minna J. The clinical behavior of „mixed”︁ small cell/large cell bronchogenic carcinoma compared to „pure”︁ small cell subtypes. Cancer 1982, 50: 2894-2902. PMID: 6291745, DOI: 10.1002/1097-0142(19821215)50:12<2894::aid-cncr2820501232>3.0.co;2-g.Peer-Reviewed Original ResearchConceptsSmall cell carcinomaSmall cell subtypeCell carcinomaResponse rateCombination chemotherapyClinical behaviorLong-term disease-free survivalCentral nervous system metastasesSmall cell carcinoma casesUntreated lung cancer patientsCell subtypesSmall cell lung cancerAggressive chemotherapy protocolsDistinct pathologic variantComplete response rateNervous system metastasesCell bronchogenic carcinomaDisease-free survivalIntensive combination chemotherapySmall cell cancerExtent of diseaseLarge cell carcinomaCell lung cancerLung cancer patientsLarge cell componentFlow cytometric analysis of DNA content of bone marrow cells in patients with plasma cell myeloma: clinical implications.
Bunn P, Krasnow S, Makuch R, Schlam M, Schechter G. Flow cytometric analysis of DNA content of bone marrow cells in patients with plasma cell myeloma: clinical implications. Blood 1982, 59: 528-35. PMID: 6800416, DOI: 10.1182/blood.v59.3.528.bloodjournal593528.Peer-Reviewed Original ResearchConceptsTumor DNA contentMyeloma patientsPlasma cell myelomaAneuploid tumor cellsPlasma cellsWaldenstrom's macroglobulinemiaCell myelomaTumor cellsTime of diagnosisTime of relapseIndependent prognostic significanceCourse of illnessClinical drug resistancePotential clinical usefulnessBone marrow cellsDNA contentClinical relapseRenal failureSerum creatininePrognostic significanceDiploid tumorsAneuploid tumorsDevelopment of aneuploidyClinical significanceClinical usefulness